Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Corticosteroids · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | PLACEBO_COMPARATOR | - |
| 4 | EXPERIMENTAL | - |
| 5 | EXPERIMENTAL | - |
| 6 | EXPERIMENTAL | - |
| 7 | PLACEBO_COMPARATOR | - |
| 8 | PLACEBO_COMPARATOR | - |
| 9 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Corticosteroids | DRUG | As prescribed |
| Placebo | DRUG | As prescribed |
| capecitabine [Xeloda] | DRUG | As prescribed |
| dexpantenol [Bepantol] | DRUG | As prescribed |
| Neoral | DRUG | Low dose (target trough level 50-100ng/mL) |
| Zenapax | DRUG | 2mg/kg iv first dose, then 1mg/kg every 2 weeks |
| mycophenolate mofetil [CellCept] | DRUG | 1g po bid |
| methotrexate | DRUG | Oral or parenteral repeating dose |
| rituximab | DRUG | Intravenous repeating dose |
Inclusion Criteria: * adult patients, \>=18 years of age; * breast cancer or colorectal cancer patients; * treated with oral Xeloda for \<=5 days; * lack of hand-foot syndrome (palmar-plantar erythrodysesthesia). Exclusion Criteria: * existence of clinical symptoms suggesting hand-foot syndrome; ...
Top 20 of 92 competitors
Corticosteroids are used for breast cancer, rheumatoid arthritis, and kidney transplantation. They are being studied in clinical trials for these conditions, including as a prophylactic treatment for hand-foot syndrome in breast cancer patients treated with capecitabine.
Corticosteroids are being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's efficacy and safety in various indications.
Corticosteroids are in Phase 3 clinical development. They are investigational and have not been approved by regulatory authorities. The drug is being studied for multiple indications, including breast cancer and kidney transplantation.
Corticosteroids are being studied in clinical trials including NCT00048152 for kidney transplantation, NCT00074438 for rheumatoid arthritis, and NCT00661102 for breast cancer. These trials have been completed and enrolled a total of 598 participants.
Corticosteroids are not the same as Zenapax (daclizumab) or CellCept (mycophenolate mofetil). In one trial, NCT00048152, corticosteroids were used in combination with these drugs to assess kidney function in transplant patients.